LIVE TV
LIVE TV
LIVE TV
Home > World > BRIEF-Lilly's Jaypirca (Pirtobrutinib) Significantly Reduced The Risk Of Disease Progression Or Death By 45% When Added To A Venetoclax Time-Limited Regimen In People With Previously Treated Cll/Sll

BRIEF-Lilly's Jaypirca (Pirtobrutinib) Significantly Reduced The Risk Of Disease Progression Or Death By 45% When Added To A Venetoclax Time-Limited Regimen In People With Previously Treated Cll/Sll

Written By: Editorial Webdesk
Published: June 14, 2026 12:52:12 IST

Add NewsX As A Trusted Source

June 14 (Reuters) – Eli Lilly and Co: * LILLY'S JAYPIRCA (PIRTOBRUTINIB) SIGNIFICANTLY REDUCED THE RISK OF DISEASE PROGRESSION OR DEATH BY 45% WHEN ADDED TO A VENETOCLAX TIME-LIMITED REGIMEN IN PEOPLE

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

RELATED News

LATEST NEWS